ES2347324T3 - Metodo de fabricacion de un forma amorfa de sal semicalcica del acido (3r,5r)7-3-fenil-4-fenilcarbamoil-2-(4-fluorofenil)-5-isopropil-pirroll-1-il)-3,5-dihidroxiheptanoico (atorvastatina). - Google Patents

Metodo de fabricacion de un forma amorfa de sal semicalcica del acido (3r,5r)7-3-fenil-4-fenilcarbamoil-2-(4-fluorofenil)-5-isopropil-pirroll-1-il)-3,5-dihidroxiheptanoico (atorvastatina). Download PDF

Info

Publication number
ES2347324T3
ES2347324T3 ES03709588T ES03709588T ES2347324T3 ES 2347324 T3 ES2347324 T3 ES 2347324T3 ES 03709588 T ES03709588 T ES 03709588T ES 03709588 T ES03709588 T ES 03709588T ES 2347324 T3 ES2347324 T3 ES 2347324T3
Authority
ES
Spain
Prior art keywords
acid
solution
atorvastatin
phenylcarbamoyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03709588T
Other languages
English (en)
Spanish (es)
Inventor
Stanislav Radl
Jan Stach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Application granted granted Critical
Publication of ES2347324T3 publication Critical patent/ES2347324T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES03709588T 2002-02-01 2003-01-30 Metodo de fabricacion de un forma amorfa de sal semicalcica del acido (3r,5r)7-3-fenil-4-fenilcarbamoil-2-(4-fluorofenil)-5-isopropil-pirroll-1-il)-3,5-dihidroxiheptanoico (atorvastatina). Expired - Lifetime ES2347324T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20020413A CZ296967B6 (cs) 2002-02-01 2002-02-01 Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
CZ20020413 2002-02-01

Publications (1)

Publication Number Publication Date
ES2347324T3 true ES2347324T3 (es) 2010-10-28

Family

ID=27674298

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03709588T Expired - Lifetime ES2347324T3 (es) 2002-02-01 2003-01-30 Metodo de fabricacion de un forma amorfa de sal semicalcica del acido (3r,5r)7-3-fenil-4-fenilcarbamoil-2-(4-fluorofenil)-5-isopropil-pirroll-1-il)-3,5-dihidroxiheptanoico (atorvastatina).

Country Status (15)

Country Link
US (1) US7208608B2 (cg-RX-API-DMAC7.html)
EP (1) EP1470106B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005521685A (cg-RX-API-DMAC7.html)
KR (1) KR20040081172A (cg-RX-API-DMAC7.html)
AT (1) ATE480516T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003213986A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ296967B6 (cg-RX-API-DMAC7.html)
DE (1) DE60334068D1 (cg-RX-API-DMAC7.html)
EA (1) EA007432B1 (cg-RX-API-DMAC7.html)
ES (1) ES2347324T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0402590A3 (cg-RX-API-DMAC7.html)
PL (1) PL209756B1 (cg-RX-API-DMAC7.html)
PT (1) PT1470106E (cg-RX-API-DMAC7.html)
UA (1) UA76826C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003068739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520740C (en) 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2005005384A1 (en) * 2003-07-15 2005-01-20 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
CA2560252C (en) * 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006008091A2 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
EP1784389A4 (en) * 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
KR20090033405A (ko) * 2004-10-18 2009-04-02 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법
WO2006048893A2 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited A process for synthesis of large particle size statin compounds
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
GB2424880A (en) * 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
CA2619486C (en) 2005-08-15 2015-05-12 Arrow International Limited Crystalline and amorphous sodium atorvastatin
AU2006281237A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) * 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
WO2010069593A1 (en) * 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
CN103108863B (zh) * 2010-04-19 2015-08-19 中化帝斯曼制药有限公司荷兰公司 低醚杂质的阿托伐他汀的制备
CN108774164A (zh) * 2018-05-29 2018-11-09 宣城美诺华药业有限公司 一种阿托伐他汀钙合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
BR9609872A (pt) * 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
PT848704E (pt) * 1995-07-17 2002-03-28 Warner Lambert Co Forma cristalina iii de um hemi-sal de calcio do acido ¬r-(r*,r*)|-2-(4-fluorofenil)-beta-delta-di-hidroxi-5-(1-metil-etil)-3-fenil-4-¬(fenilamino)carbonil|-1h-pirrole-1-heptanico(atorvastatina)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IN191236B (cg-RX-API-DMAC7.html) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
IN190564B (cg-RX-API-DMAC7.html) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)

Also Published As

Publication number Publication date
KR20040081172A (ko) 2004-09-20
DE60334068D1 (de) 2010-10-21
UA76826C2 (uk) 2006-09-15
EA200400977A1 (ru) 2004-12-30
CZ296967B6 (cs) 2006-08-16
EP1470106A1 (en) 2004-10-27
PL370495A1 (en) 2005-05-30
HUP0402590A3 (en) 2010-06-28
JP2005521685A (ja) 2005-07-21
ATE480516T1 (de) 2010-09-15
US20050131055A1 (en) 2005-06-16
US7208608B2 (en) 2007-04-24
CZ2002413A3 (cs) 2003-10-15
WO2003068739A1 (en) 2003-08-21
EA007432B1 (ru) 2006-10-27
PT1470106E (pt) 2010-09-23
PL209756B1 (pl) 2011-10-31
AU2003213986A1 (en) 2003-09-04
HUP0402590A2 (hu) 2005-03-29
EP1470106B1 (en) 2010-09-08

Similar Documents

Publication Publication Date Title
PT1470106E (pt) Um método de fabricar uma forma amorfa do sal hemi-cálcico do ácido (3r,5r)-7-3-fenil-4-fenilcarbamoil-2-(4- fluorofenil)-5-isopropil-pirrol-1-il-3,5-di-hidroxiheptanóico (atorvastatina)
ES2669052T3 (es) Método de preparación de acetato de ulipristal y sus intermedios
ES2388371T3 (es) N-{1-[3-(2-etoxi-5-(4-etilpiperazinil)bencenosulfonil)-4,5-dihidro-5-oxo-1,2,4-triazin-6-il]etil}-butiramida, método de preparación y uso
HUP0300073A2 (en) Method of purifying a fermentation broth
AU2004217988A1 (en) Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
AU2001236543A1 (en) Method of purifying a fermentation broth
CZ2005427A3 (cs) Zpusob výroby hemivápenáté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
WO2008058118A2 (en) Preparation of montelukast and its salts
CN101723971B (zh) 1β-甲基碳青霉烯类抗生素双环母核的制备方法
ES2305848T3 (es) Base cristalina de alfuzosina.
ES2710312T3 (es) Un procedimiento para la preparación de montelukast sódico
ES2302032T3 (es) Procedimiento para la preparacion de z-flupentixol.
JPH07224077A (ja) 9−(z)−レチノイン酸の製法
US20060074242A1 (en) Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I
AU2009264395B2 (en) Process for the preparation of clopidogrel hydrogen sulfate crystalline form I
CA2567806C (en) Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph - form i
CZ300692B6 (cs) Zpusob prípravy solifenacinu
RU2707043C1 (ru) Способ получения гербицида имазамокса
SU1631067A1 (ru) Способ получени докозагексаеновой, эйкозапентаеновой и арахидоновой кислот или их смеси
AU2007284927A1 (en) Process for making lactam tachykinin receptor antagonists
KR20070053697A (ko) 개선된 미르타자핀 제조방법
ES2533212T3 (es) Sal canforsulfónica de intermedio de montelukast
US6121306A (en) Method of making (1S, 4R)-1-azabicyclo[2.2.1]heptan-3-one and (1R, 4S), 1-azabicyclo[2.2.1]heptan-3-one
JPH08325262A (ja) (+)−3−フェニル−5−{2−(1−ピロリジニルメチル)ブチリル}イソオキサゾールおよびその塩の製造法
CN119219540A (zh) 一种奥拉西坦及其光学异构体的关键中间体及其制备方法和应用